Updated:
Laborie Medical Technologies
Founded in 1967 in Montreal, Laborie Medical Technologies spent its first five decades as a focused manufacturer of urodynamics equipment under founder...
Laborie Medical Technologies
Founded in 1967 in Montreal, Laborie Medical Technologies spent its first five decades as a focused manufacturer of urodynamics equipment under founder Raymond Laborie. The company earned a reputation for clinical precision in a narrow niche — measuring bladder function — before private equity interest reshaped its trajectory. In 2016, Patricia Industries, a division of Sweden's Investor AB, acquired Laborie and moved its headquarters to Portsmouth, New Hampshire, initiating an aggressive acquisition campaign. That acquisition campaign defines Laborie's current identity. The company now operates across three integrated segments: urology, urogynecology, and gastroenterology. Its product catalog flows from diagnostic systems — such as the water-perfused catheters it was built on — into a wide range of therapeutic devices, including slings for female stress urinary incontinence, urethral bulking agents, and single-use catheters for intermittent self-catheterization. Since 2016, Laborie has completed more than a dozen add-on acquisitions (per healthcare M&A databases, 2024), absorbing companies like Cogentix Medical, Clinical Innovations, and EndoGastric Solutions. The firm distributes in over 90 countries, with direct commercial teams in the United States, Canada, the United Kingdom, the Netherlands, and France. Patricia Industries does not publicly disclose Laborie's standalone revenue, but industry analysts and consolidator comparables suggest the platform crossed $500 million in annual revenue by 2023 (Altss estimate). In January 2024, Investor AB's annual report highlighted Laborie as one of the larger holdings within Patricia Industries, noting its transition toward recurring revenue through single-use device sales. Laborie is not independently listed and operates as a wholly owned subsidiary within a structure that includes other medical technology platforms like BraunAbility and Sarnova. Laborie's structural differentiator is its status as a proprietary consolidation engine within a permanent-capital holding company. Unlike a typical private equity fund that must exit within a defined window, Patricia Industries — backed by the Wallenberg family's Investor AB — has no forced timeline. This allows Laborie to integrate acquisitions into a single commercial and R&D organization rather than treating them as disconnected portfolio companies, creating an unusual hybrid between a medical device manufacturer and a long-duration holding vehicle.
General information
Firm type
Asset Manager
Year founded
1967
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Portsmouth
Corporate office
Portsmouth, NH, United States
Sector focus
Frequently asked questions
Who owns Laborie Medical Technologies and how does that ownership structure affect its investment horizon?
Patricia Industries, a division of Investor AB — the publicly listed holding company of the Swedish Wallenberg family — has owned Laborie since 2016. Because Investor AB typically holds assets indefinitely rather than cycling them through five-to-seven-year fund vehicles, Laborie operates with permanent capital. This allows the company to integrate acquisitions fully into a single operating structure without pressure to resell within a predetermined window.
How has Laborie's business model shifted since the Patricia Industries acquisition?
Since 2016, Laborie has moved from a manufacturer of capital equipment — primarily urodynamics systems — toward a model emphasizing recurring revenue from consumables. This includes single-use catheters, diagnostic disposables, and therapeutic devices. The pivot was driven by the 2019 acquisition of Cogentix Medical and subsequent deals for Clinical Innovations and EndoGastric Solutions, each adding layers of disposable product lines to the catalog.
What is Laborie's geographic footprint?
Laborie distributes products in more than 90 countries, with direct sales offices in the United States, Canada, the United Kingdom, the Netherlands, and France. The company's primary manufacturing and R&D centers are in North America, though several acquired subsidiaries brought European and Asia-Pacific distribution networks into the fold.
Does Laborie participate in external capital raises or operate as an independent acquirer?
No. Laborie does not raise external funds and is not an independent acquirer. All acquisitions are funded through Patricia Industries' balance sheet. The company does not manage outside capital, nor does it operate as a family office or investment firm — it is an operating medical device company that grows through M&A executed by its parent.
Which therapeutic areas does Laborie address, and where are the boundaries of its consolidation strategy?
Laborie consolidates companies in urology, urogynecology, and gastroenterology. Within those areas, it covers diagnostics (urodynamics, anorectal manometry), therapeutics (surgical slings, bulking agents, reflux treatments), and consumables (intermittent catheters). The firm has not expanded into adjacent fields like nephrology or oncology devices, focusing instead on deepening its presence within pelvic health.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: